Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shandong Lukang Pharmaceutical Co Ltd Receives Drug Registration Approval


Monday, 15 Jul 2013 08:00pm EDT 

Shandong Lukang Pharmaceutical Co Ltd announced that it has received drug registration approval for entecavir active pharmaceutical ingredient and two specifications tablet with number of H20130060, H20130061 and H20130062 from China Food and Drug Administration. entecavir is used for treatment of adult chronic hepatitis B. 

Company Quote